In this episode, hosts Katie Perry and Austin Hankwitz explore atai Life Sciences with Founder and Chairman Christian Angermayer, covering its mission and the rise of mental health issues. Together, they discuss the current state of psychedelic regulation, atai’s drug development phases, how retail investors should approach Atai post-product launch, and the company’s go-to-market strategy.

$ATAI

00:00:00 START

00:01:20 What is atai Life Sciences?

00:08:55 The prevailing theory on the rapid rise of mental health issues

00:15:50 Regulatory bodies’ openness to collaborating with atai

00:17:58 The current state of the regulation process for psychedelics

00:19:17 Phases of drug development and where atai currently is

00:24:00 How retail investors should be thinking about atai once the products go live

00:27:10 atai’s go-to-market strategy

00:32:09 Current world leader who should have the psychedelic experience

00:35:28 What retail investors should be looking at in atai’s earnings

00:40:13 Longevity and anti-aging effects of psychedelics

After Earnings is brought to you by Stakeholder Labs and Morning Brew.

For more go to https://www.afterearnings.com

Follow Us

X: https://twitter.com/AfterEarnings

TikTok: https://www.tiktok.com/@AfterEarnings

Instagram: https://www.instagram.com/afterearnings_/

Reach Out

Email: [email protected]

Learn more about your ad choices. Visit megaphone.fm/adchoices